Interleukin-7 inhibitors and the Interleukin-1 inhibitors (IL-1) inhibitor Anakinra (Kineret) and Canakinumab (Ilaris) for COVID-19 Treatment In severe, COVID-19 infection the lung tissues abundantly produce IL-1, IL-6, IL-12, Tumor Necrosis factor –alpha (TNFα) and many other inflammatory mediators. This is called cytokine storm. The active inflammatory response often creates increased alveolar-capillary gas exchange. Ultimately, oxygenation at the alveolar level becomes difficult and the condition of patient deteriorates. To prevent any deterioration of condition, interleukin inhibitors are recommended in the treatment of COVID-19.